Financials
- Financial year
- 2025
- Total assets
- €422,491
- Profit
- €233,425
- Solvency
- 63.7%
Total assets▲ 78.8%
Net result
20182025
ID3 MEDICAL
ActiveSummary
ID3 MEDICAL has been active since 2013 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €269,159 and a net result of €233,425. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 69% of 13,668 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Overview
Activity
Wholesale of pharmaceutical and medical goods
NACE 46460
1 site
Size
≈ €2.0mturnover 2025, estimated
- Staff
- 2 FTE
- Equity
- €269,159
- Profit
- €233,425
Turnover estimated from the gross margin
Structure
- M-CONCEPTSDirector · permanent representative MAENE Lieven
- PodimmedDirector · permanent representative DELOOSE Koen
2025 accounts 30 days early1 of 3 deeds summarised
Why 98lowers riskLiquidity: current ratio 2.75, cash €85,388Founded in 2013Equity €269,159 (63.7% of total assets)Figures for financial year 2025 (filed 01-07-2026)Show the evidence
Checked score
Score 2025
98
/ 100
Excellent
Probability in this band: under 0.55%
Financially better than 81% of its sector peers (NACE 46, micro)
Financial strength · tick = 2024
Strong
Solvency
89+7
equity 63.7% of total assets
Liquidity
59+14
short-term debt 36.3% · cash 20.2%
Profitability
100+28
return on assets 55.2%
Bankruptcy probability, 12 months
0.1%
Very low
0%0.5%1.5%4%10%≥ 25%
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
11-2024: 0.7%
12-2024: 0.7%● unchanged vs 11-2024
01-2025: 0.7%● unchanged vs 12-2024
02-2025: 0.7%● unchanged vs 01-2025
03-2025: 0.6%▼ -0.1 percentage points vs 02-2025
04-2025: 0.7%▲ +0.1 percentage points vs 03-2025
05-2025: 0.6%▼ -0.1 percentage points vs 04-2025
06-2025: 0.6%● unchanged vs 05-2025
07-2025: 0.7%▲ +0.1 percentage points vs 06-2025
08-2025: 0.9%▲ +0.2 percentage points vs 07-2025highest value
09-2025: 0.1%▼ -0.8 percentage points vs 08-2025
10-2025: 0.1%● unchanged vs 09-2025
11-2025: 0.1%● unchanged vs 10-2025
12-2025: 0.1%● unchanged vs 11-2025
01-2026: 0.1%● unchanged vs 12-2025
02-2026: 0.1%● unchanged vs 01-2026
03-2026: 0.1%● unchanged vs 02-2026
04-2026: 0.1%● unchanged vs 03-2026
05-2026: 0.1%● unchanged vs 04-2026
06-2026: 0.1%● unchanged vs 05-2026
07-2026: 0.2%▲ +0.1 percentage points vs 06-2026
08-2026: 0.1%▼ -0.1 percentage points vs 07-2026lowest value
09-2026: 0.1%● unchanged vs 08-2026lowest value
10-2026: 0.1%● unchanged vs 09-2026lowest value
Credit of up to €25,000 on 30-day terms is acceptable
Liquidity ample (current ratio 2.75, compared with 2.32 in 2024, above the usual 1.5; short-term debt: 36.3% and cash: 20.2% of total assets), and 36.3% of the assets are financed with debt and provisions.
How it is calculated
The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, micro): better than 70% on solvency, 65% on liquidity, 95% on profitability and 93% on growth.
The bankruptcy probability was computed on 29-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).
Credit check for your own amount and term
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
Six signals.
lowers riskneutral
lowers risk · Growing equity
Reported equity is higher than in 2023 and did not fall compared with 2024. These amounts do not establish the cause of the change.
NBB · annual accounts 2025Equity per financial year
1819202122232425
2018 to 2025 · latest year €269,159
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 01-07-2026, 30 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
30 days early
2024
1 day early
2023
30 days late
2022
3 days early
2021
19 days early
2020
33 days early
2019
3 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 8 days before the deadline; the sector median (NACE 46) for financial year 2024 is 3 days before the deadline, and 39% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 28 July (4 of the last 5 filed years within 30 days of that day).
Companies Code · seven monthsWhere today falls in the filing period
30-10-2026 today31-12-2026 year end31-07-2027 deadline
- Annual accounts filedfinancial year 2025 · micro…
- Highest result from 2018 to 2025net €233,425 ▲3,853%
- Equity above €200,000equity €269,159 ▲98.3%
Key points
By topic
Board & ownership
- Board
- 2 members
- M-CONCEPTSDirector
- PodimmedDirector
Network & group
- Connected companies
- 1
Timeline
- Events
- 21
- Since
- 2015
- Next accounts
- by 31-07-2027
- 30-07-2025Annual accounts filed
- 31-12-2024Back to profit
- 30-08-2024Annual accounts filed
Company details
- Sites
- 1
- Legal form
- Private limited company
- Activity
- Wholesale of pharmaceutical and medical goodsNACE 46460
- Founded
- 13-11-2013
- Year ends
- 31-12
- Peppol
- Reachable for e-invoices
Articles of association
- Provisions read
- 24
- Annual meeting
- Last Friday of June at 16:00
Key facts about ID3 MEDICAL
- What is the company number of ID3 MEDICAL?
- 0541.834.476. In Belgium the VAT number is the company number with BE in front: BE 0541.834.476.
- Where is ID3 MEDICAL based?
- The registered office is at Keizer Karellaan 584, 1082 Sint-Agatha-Berchem.Company details
- What does ID3 MEDICAL do?
- According to the KBO register, the main activity is wholesale of pharmaceutical and medical goods (NACE 46460).
- What is the legal form of ID3 MEDICAL?
- Private limited company (BV).
- When was ID3 MEDICAL founded?
- On 13-11-2013.
- Is ID3 MEDICAL still active?
- Yes, ID3 MEDICAL is an active enterprise in the KBO register.
- How many employees does ID3 MEDICAL have?
- On average 2 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- What is the turnover of ID3 MEDICAL?
- Not stated in the processed annual accounts. The abridged format for small companies does not require turnover.
- Is ID3 MEDICAL profitable?
- In financial year 2025, ID3 MEDICAL made a profit of €233,425.
- Where can I find the annual accounts of ID3 MEDICAL?
- ID3 MEDICAL filed 12 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of ID3 MEDICAL due?
- By 31-07-2027, for financial year 2026.Timeline
Companies related to ID3 MEDICAL
Comparable companies
- SIMOVISIONOverijse
- MedtradexOud-Heverlee
- PROTECT AND CAREGent
- ALL MODULIeper
- ColorgrapeGrimbergen
Go further with this company
How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.